TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Integrated Community Case Management of Common Childhood Diseases: Mozambique and Uganda
Brief Summary: The aim of the inSCALE project is to test the effect of innovative approaches to increase coverage of integrated community case management, which provides community based-care for diarrhoea, pneumonia and malaria, resulting in more children receiving timely and appropriate care for these three most common childhood illnesses


Options:
A: Arm Label: 5As Team Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: 5As Team Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: 5As Team Intervention; Assigned to Arm(s): 5As Team Intervention
B: Arm Label: Shared decision-making program; Type: EXPERIMENTAL; Interventions: Other: Shared decision-making program | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Shared decision-making program; Assigned to Arm(s): Shared decision-making program | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care
C: Arm Label: Technology supported supervision; Type: EXPERIMENTAL; Interventions: Other: Technology supported supervision, Other: Integrated community case management | Arm Label: Community supported supervision; Type: EXPERIMENTAL; Interventions: Behavioral: Community supported supervision, Other: Integrated community case management | Arm Label: Control arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Integrated community case management | Intervention Type: OTHER; Name: Technology supported supervision; Assigned to Arm(s): Technology supported supervision | Intervention Type: BEHAVIORAL; Name: Community supported supervision; Assigned to Arm(s): Community supported supervision | Intervention Type: OTHER; Name: Integrated community case management; Assigned to Arm(s): Community supported supervision, Control arm, Technology supported supervision
D: Arm Label: Education-only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Healthy Lifestyles Clinic | Arm Label: Bull City Fit Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Bull City Healthy and Fit | Intervention Type: BEHAVIORAL; Name: Bull City Healthy and Fit; Assigned to Arm(s): Bull City Fit Intervention | Intervention Type: BEHAVIORAL; Name: Healthy Lifestyles Clinic; Assigned to Arm(s): Education-only

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Integrated Community Case Management of Common Childhood Diseases: Mozambique and Uganda
Brief Summary: The aim of the inSCALE project is to test the effect of innovative approaches to increase coverage of integrated community case management, which provides community based-care for diarrhoea, pneumonia and malaria, resulting in more children receiving timely and appropriate care for these three most common childhood illnesses


Options:
A: Arm Label: Teledermatology; Type: EXPERIMENTAL; Interventions: Other: Teledermatology | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Teledermatology; Assigned to Arm(s): Teledermatology
B: Arm Label: SINEMA intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: SINEMA intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SINEMA intervention; Assigned to Arm(s): SINEMA intervention group
C: Arm Label: Technology supported supervision; Type: EXPERIMENTAL; Interventions: Other: Technology supported supervision, Other: Integrated community case management | Arm Label: Community supported supervision; Type: EXPERIMENTAL; Interventions: Behavioral: Community supported supervision, Other: Integrated community case management | Arm Label: Control arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Integrated community case management | Intervention Type: OTHER; Name: Technology supported supervision; Assigned to Arm(s): Technology supported supervision | Intervention Type: BEHAVIORAL; Name: Community supported supervision; Assigned to Arm(s): Community supported supervision | Intervention Type: OTHER; Name: Integrated community case management; Assigned to Arm(s): Community supported supervision, Control arm, Technology supported supervision
D: Arm Label: eConsult; Type: EXPERIMENTAL; Interventions: Other: Champlain BASE eConsult Service | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Champlain BASE eConsult Service; Assigned to Arm(s): eConsult

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open Label, Single Centre, Phase II Pilot Study of Neoadjuvant Dabrafenib + Trametinib in Patients With Resectable American Joint Committee on Cancer (AJCC) Stage IIIB-C BRAF V600 Mutation Positive Melanoma
Brief Summary: This is an open label, single centre, phase II study of neoadjuvant drug treatment with dabrafenib + trametinib in patients with resectable American Joint Committee on Cancer (AJCC) Stage IIIB-C BRAF V600 mutation positive melanoma.

The main aim of this study is to find out if giving of a new combined drug treatment to patients with melanoma that has spread to the lymph nodes BEFORE they have surgery, will result in improved clinical and pathological response of the melanoma tissue after 12 weeks treatment.


Options:
A: Arm Label: Dabrafenib and Trametinib; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Dabrafenib and Trametinib | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Dabrafenib and Trametinib
B: Arm Label: Vemurafenib, pill, twice daily; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib, Drug: Cobimetinib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib, pill, twice daily | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): Vemurafenib, pill, twice daily
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ipilimumab | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ipilimumab; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
D: Arm Label: Arm A: Adjuvant Nivolumab (Complete Pathological Response); Type: ACTIVE_COMPARATOR; Interventions: Drug: nivolumab | Arm Label: Arm B: Adjuvant Nivolumab (Less than Complete Response); Type: ACTIVE_COMPARATOR; Interventions: Drug: nivolumab | Arm Label: Arm C: Adjuvant Combination (Less than Complete Response); Type: EXPERIMENTAL; Interventions: Drug: nivolumab, Drug: Ipilimumab | Intervention Type: DRUG; Name: nivolumab; Assigned to Arm(s): Arm A: Adjuvant Nivolumab (Complete Pathological Response), Arm B: Adjuvant Nivolumab (Less than Complete Response), Arm C: Adjuvant Combination (Less than Complete Response) | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Arm C: Adjuvant Combination (Less than Complete Response)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Study of Tivozanib as Maintenance Therapy, Post-Chemotherapy, in Patients With Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Brief Summary: This research study is evaluating a drug called tivozanib as a possible treatment for ovarian, fallopian tube or primary peritoneal cancer.

Angiogenesis is the formation of new blood vessels. Tumors need blood vessels to grow and spread. Tivozanib is an anti-angiogenesis medicine that fights cancer by cutting off a tumor's blood supply so that it does not get the blood and nutrients it needs to grow.

In this research study, the Investigators are looking to see whether tivozanib works as a maintenance therapy for ovarian, fallopian tube or primary peritoneal carcinoma in participants who have achieved a complete response following chemotherapy. Maintenance therapy is given after a disease has responded to previous treatment. It is given to help prevent the spread or recurrence of the tumor.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): 2
B: Arm Label: Placebo plus PLD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo plus PLD | Arm Label: AMG386 plus PLD; Type: EXPERIMENTAL; Interventions: Drug: AMG386 plus PLD | Intervention Type: DRUG; Name: AMG386 plus PLD; Assigned to Arm(s): AMG386 plus PLD | Intervention Type: DRUG; Name: Placebo plus PLD; Assigned to Arm(s): Placebo plus PLD
C: Arm Label: Tivozanib; Type: EXPERIMENTAL; Interventions: Drug: Tivozanib | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Tivozanib; Assigned to Arm(s): Tivozanib
D: Arm Label: Arm 1: Niraparib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Niraparib | Arm Label: Arm 2: Niraparib and Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Niraparib | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm 2: Niraparib and Bevacizumab | Intervention Type: DRUG; Name: Niraparib; Assigned to Arm(s): Arm 1: Niraparib, Arm 2: Niraparib and Bevacizumab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Foley Catheter Versus Oxytocin for Labor Induction in Women With Term and Near Term Premature Rupture of Membranes: A Randomized Clinical Trial (FOLCROM Trial)
Brief Summary: Multicenter randomized clinical trial comparing oxytocin versus oxytocin and foley catheter for induction in women who present with premature rupture of membranes who are not in labor.


Options:
A: Intervention Type: DRUG; Name: low dose oxytocin; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: ARD (Atad Ripener Device) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: AID (Atad double balloon Instillation Device) | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Device: folly catheter | Intervention Type: DEVICE; Name: ARD (Atad Ripener Device); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: AID (Atad double balloon Instillation Device); Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: folly catheter; Assigned to Arm(s): 3
C: Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: Foley Catheter and Oxytocin; Type: EXPERIMENTAL; Interventions: Device: Foley Catheter, Drug: Oxytocin | Intervention Type: DEVICE; Name: Foley Catheter; Assigned to Arm(s): Foley Catheter and Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Foley Catheter and Oxytocin, Oxytocin
D: Arm Label: sequential; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol, Device: Foley Catheter | Arm Label: Concurrent; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol, Device: Foley Catheter | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Concurrent, sequential | Intervention Type: DEVICE; Name: Foley Catheter; Assigned to Arm(s): Concurrent, sequential

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Foley Catheter Versus Oxytocin for Labor Induction in Women With Term and Near Term Premature Rupture of Membranes: A Randomized Clinical Trial (FOLCROM Trial)
Brief Summary: Multicenter randomized clinical trial comparing oxytocin versus oxytocin and foley catheter for induction in women who present with premature rupture of membranes who are not in labor.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: dinoprostone | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Device: Bard Catheter (balloon catheter) | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: dinoprostone; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: Bard Catheter (balloon catheter); Assigned to Arm(s): 3
B: Arm Label: FOLEY BALLOON; Type: ACTIVE_COMPARATOR; Interventions: Device: FOLEY BALLOON | Arm Label: CERVIDIL; Type: ACTIVE_COMPARATOR; Interventions: Drug: CERVIDIL (Dinoprostone) | Intervention Type: DRUG; Name: CERVIDIL (Dinoprostone); Assigned to Arm(s): CERVIDIL | Intervention Type: DEVICE; Name: FOLEY BALLOON; Assigned to Arm(s): FOLEY BALLOON
C: Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: Foley Catheter and Oxytocin; Type: EXPERIMENTAL; Interventions: Device: Foley Catheter, Drug: Oxytocin | Intervention Type: DEVICE; Name: Foley Catheter; Assigned to Arm(s): Foley Catheter and Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Foley Catheter and Oxytocin, Oxytocin
D: Arm Label: weighted bag; Type: ACTIVE_COMPARATOR; Interventions: Other: weighted bag | Arm Label: leg taping; Type: ACTIVE_COMPARATOR; Interventions: Other: leg taping | Intervention Type: OTHER; Name: weighted bag; Assigned to Arm(s): weighted bag | Intervention Type: OTHER; Name: leg taping; Assigned to Arm(s): leg taping

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacist-Physician Collaborative Medication Therapy Management Services (MTMS) Demonstration Project
Brief Summary: Patients managed by a newly formed pharmacist-physician medication therapy management team in a university primary care clinic will have better blood pressure control than patients receiving usual care.


Options:
A: Arm Label: Extended Treatment Group; Type: EXPERIMENTAL; Interventions: Device: Glucose and lipids, Device: Glycosylated Hemoglobin A1c, Device: Blood Pressure and Heart Rate, Device: Body mass index, Device: Waist and Hip circumference, Behavioral: Comprehensive Medication Management | Arm Label: Usual Treatment Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Glucose and lipids, Device: Glycosylated Hemoglobin A1c, Device: Blood Pressure and Heart Rate, Device: Body mass index, Device: Waist and Hip circumference | Intervention Type: DEVICE; Name: Glucose and lipids; Assigned to Arm(s): Extended Treatment Group, Usual Treatment Group | Intervention Type: DEVICE; Name: Glycosylated Hemoglobin A1c; Assigned to Arm(s): Extended Treatment Group, Usual Treatment Group | Intervention Type: DEVICE; Name: Blood Pressure and Heart Rate; Assigned to Arm(s): Extended Treatment Group, Usual Treatment Group | Intervention Type: DEVICE; Name: Body mass index; Assigned to Arm(s): Extended Treatment Group, Usual Treatment Group | Intervention Type: DEVICE; Name: Waist and Hip circumference; Assigned to Arm(s): Extended Treatment Group, Usual Treatment Group | Intervention Type: BEHAVIORAL; Name: Comprehensive Medication Management; Assigned to Arm(s): Extended Treatment Group
B: Arm Label: Advanced care; Type: OTHER; Interventions: Other: Advanced Care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Advanced Care; Assigned to Arm(s): Advanced care
C: Arm Label: Pharmacist-Physician Collaborative Medication Management; Type: EXPERIMENTAL; Interventions: Other: Pharmacist-Physician Collaborative Medication Therapy Management | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pharmacist-Physician Collaborative Medication Therapy Management; Assigned to Arm(s): Pharmacist-Physician Collaborative Medication Management
D: Arm Label: Health service provision; Type: EXPERIMENTAL; Interventions: Procedure: Pharmacist-Initiated Intervention in OsteoArthritis (PhIT-OA) | Intervention Type: PROCEDURE; Name: Pharmacist-Initiated Intervention in OsteoArthritis (PhIT-OA); Assigned to Arm(s): Health service provision

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacist-Physician Collaborative Medication Therapy Management Services (MTMS) Demonstration Project
Brief Summary: Patients managed by a newly formed pharmacist-physician medication therapy management team in a university primary care clinic will have better blood pressure control than patients receiving usual care.


Options:
A: Arm Label: MEDIC; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral counseling and peer support, Behavioral: Interactive Education, Behavioral: Role modeling, Procedure: Pharmacologic case management | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral counseling and peer support; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Interactive Education; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Role modeling; Assigned to Arm(s): MEDIC | Intervention Type: PROCEDURE; Name: Pharmacologic case management; Assigned to Arm(s): MEDIC
B: Arm Label: Pharmacist-Physician Collaborative Medication Management; Type: EXPERIMENTAL; Interventions: Other: Pharmacist-Physician Collaborative Medication Therapy Management | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pharmacist-Physician Collaborative Medication Therapy Management; Assigned to Arm(s): Pharmacist-Physician Collaborative Medication Management
C: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Other: High Intensity Intervention, Other: All- 6 month pharmacist intervention | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Low Intensity Intervention, Other: All- 6 month pharmacist intervention | Intervention Type: OTHER; Name: High Intensity Intervention; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Low Intensity Intervention; Assigned to Arm(s): Arm 2 | Intervention Type: OTHER; Name: All- 6 month pharmacist intervention; Assigned to Arm(s): Arm 1, Arm 2
D: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Self-management; Type: EXPERIMENTAL; Interventions: Other: Self-monitoring and adjustment of oral anticoagulation | Intervention Type: OTHER; Name: Self-monitoring and adjustment of oral anticoagulation; Assigned to Arm(s): Self-management

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventing Childhood Obesity Through a Family-Based Mindfulness Intervention
Brief Summary: The goal of the proposed interdisciplinary study is to assess feasibility of recruiting a pilot sample of parents of toddlers and engaging them in a pilot study to test a version of mindfulness-based intervention for parenting stress reduction (PMH), an empirically-supported stress-reduction intervention, plus nutrition and physical activity counseling for parents of preschoolers (aged 2-5); to reduce parent (and child) stress levels; improve parenting; promote healthy eating and physical activity in parent and child; and prevent overweight and obesity in preschoolers with an obese parent.


Options:
A: Arm Label: Child-focused Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Parent-implemented Early Start Denver Model | Arm Label: Child- and Parent-focused Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Parent-implemented Early Start Denver Model, Behavioral: Mindfulness Based Stress Reduction | Intervention Type: BEHAVIORAL; Name: Parent-implemented Early Start Denver Model; Assigned to Arm(s): Child- and Parent-focused Treatment, Child-focused Treatment | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Stress Reduction; Assigned to Arm(s): Child- and Parent-focused Treatment
B: Arm Label: AMOR Method; Type: EXPERIMENTAL; Interventions: Behavioral: The AMOR Method | Arm Label: Wait List; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The AMOR Method; Assigned to Arm(s): AMOR Method
C: Arm Label: lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle counseling | Arm Label: therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle counseling, Behavioral: Parenting Mindfully for Health (PMH) | Intervention Type: BEHAVIORAL; Name: Lifestyle counseling; Assigned to Arm(s): lifestyle, therapy | Intervention Type: BEHAVIORAL; Name: Parenting Mindfully for Health (PMH); Assigned to Arm(s): therapy
D: Arm Label: Parenting Mindfully Program; Type: EXPERIMENTAL; Interventions: Behavioral: Parenting Mindfully Program | Arm Label: Parent Education Program; Type: ACTIVE_COMPARATOR; Interventions: Other: Parent Education Program | Intervention Type: BEHAVIORAL; Name: Parenting Mindfully Program; Assigned to Arm(s): Parenting Mindfully Program | Intervention Type: OTHER; Name: Parent Education Program; Assigned to Arm(s): Parent Education Program

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
Brief Summary: This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and unstable angina requiring urgent revascularization, in high risk subjects who are receiving background lipid lowering therapy and have cholesterol laboratory values of LDL-C \>/= 70 mg/dL (1.8 mmol/L) or non-HDL-C \>/= 100 mg /dL (2.6 mmol/L).


Options:
A: Arm Label: Alirocumab therapy group; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab | Arm Label: standard statin therapy group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab therapy group
B: Arm Label: Q28d Dosing Arm; Type: EXPERIMENTAL; Interventions: Drug: PBO, Drug: 200mg PF-04950615 (RN316), Drug: 300mg PF-04950615 (RN316) | Arm Label: Q14d Dosing Arm; Type: EXPERIMENTAL; Interventions: Drug: PBO, Drug: PF-04950615 | Intervention Type: DRUG; Name: PBO; Assigned to Arm(s): Q28d Dosing Arm | Intervention Type: DRUG; Name: 200mg PF-04950615 (RN316); Assigned to Arm(s): Q28d Dosing Arm | Intervention Type: DRUG; Name: 300mg PF-04950615 (RN316); Assigned to Arm(s): Q28d Dosing Arm | Intervention Type: DRUG; Name: PBO; Assigned to Arm(s): Q14d Dosing Arm | Intervention Type: DRUG; Name: PF-04950615; Assigned to Arm(s): Q14d Dosing Arm | Intervention Type: DRUG; Name: PF-04950615; Assigned to Arm(s): Q14d Dosing Arm | Intervention Type: DRUG; Name: PF-04950615; Assigned to Arm(s): Q14d Dosing Arm
C: Arm Label: bococizumab (PF-04950615); Type: EXPERIMENTAL; Interventions: Drug: bococizumab (PF-04950615) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: bococizumab (PF-04950615); Assigned to Arm(s): bococizumab (PF-04950615) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Alirocumab 75 /up to 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Placebo (for ezetimibe), Drug: Lipid Modifying Therapy (LMT) | Arm Label: Ezetimibe 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Ezetimibe, Drug: Lipid Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Placebo (for ezetimibe); Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W | Intervention Type: DRUG; Name: Lipid Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W, Ezetimibe 10 mg

Answer: C